AKT1 and osteosarcoma: In conclusion, the present study provides comprehensive evidence for the inhibition of dioscin on osteosarcoma stem-cell-like properties and tumor growth through repression of Akt/GSK3/β-catenin pathway, which suggests dioscin as a promising therapeutic regimen without obvious side effects for osteosarcoma patients.